AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
27 September 2023 - 11:00PM
Business Wire
AbCellera (Nasdaq: ABCL) today announced two upcoming poster
presentations on its T-cell engager platform at the Society for
Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held
virtually and at the San Diego Convention Center from November 1 to
5, 2023.
“We have made significant progress on the application of our
T-cell engager platform since we presented data at SITC in 2022,”
said Bo Barnhart, Ph.D., VP, Translational Research at AbCellera.
“We’re looking forward to presenting two posters this year
demonstrating how key insights into CD3 T-cell engager biology help
us to execute on our programs for various tumor targets, including
a challenging peptide-MHC target.”
Details on AbCellera’s poster presentations at SITC are as
follows:
Title: A rational approach for selecting CD3-binding
antibodies for T-cell engager development Abstract Number:
1367 Date and Time: Friday, November 3 from 9:00 a.m. to
7:00 p.m. PDT Location: San Diego Convention Center, Exhibit
Halls A and B1 or online at https://www.sitcancer.org/2023/home
Title: Targeting intracellular tumor antigens to fight
cancer: Discovery and development of functional and specific T-cell
engagers against a MAGE-A4 pMHC Abstract Number: 1395
Date and Time: Friday, November 3 from 9:00 a.m. to 7:00
p.m. PDT Location: San Diego Convention Center, Exhibit
Halls A and B1 or online at https://www.sitcancer.org/2023/home
About T-Cell Engagers
CD3 T-cell engagers are bispecific antibodies that guide the
immune system to find and eliminate cancer cells by binding both
cancer-killing T cells and tumor targets at the same time.
Developing effective T-cell engagers requires two parental
antibodies—a CD3-binding arm that fine-tunes T-cell activation and
a tumor-binding arm with high specificity for cancer cells. The
small number of available CD3-binding antibodies that can
effectively fine-tune T-cell responses has been a barrier to T-cell
engager development. To address this barrier, AbCellera developed a
complete T-cell engager platform that includes fully human,
developable CD3-binding antibodies with unique binding and
functional properties. By combining these antibodies with
OrthoMabTM, its clinically validated multispecific engineering
platform, and its antibody discovery and development engine,
AbCellera’s T-cell engager platform is designed to bring new cancer
medicines to the clinic faster.
About AbCellera Biologics Inc.
AbCellera is breaking the barriers of conventional antibody drug
discovery to bring better medicines to patients, sooner.
AbCellera’s engine integrates expert teams, technology, and
facilities with the data science and automation needed to propel
antibody-based medicines from target to clinic in nearly every
therapeutic area with precision and speed. AbCellera provides
innovative biotechs and leading pharmaceutical companies with a
competitive advantage that empowers them to move quickly, reduce
cost, and tackle the toughest problems in drug development. For
more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230925344820/en/
Inquiries Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236)521-6774 Business Development: Murray
McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor
Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com,
+1(778)729-9116
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Apr 2024 to May 2024
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From May 2023 to May 2024